Experts from the European Society of Hypertension prepared this position paper in order to summarize current evidence, unmet needs and practical recommendations on the application of percutaneous transluminal ablation of renal nerves [renal denervation (RDN)] as a novel therapeutic strategy for the treatment of resistant hypertension. The sympathetic nervous activation to the kidney and the sensory afferent signals to the central nervous system represent the targets of RND. Clinical studies have documented that catheter-based RDN decreases both efferent sympathetic and afferent sensory nerve traffic leading to clinically meaningful systolic and diastolic blood pressure (BP) reductions in patients with resistant hypertension. This position statement intends to facilitate a better understanding of the effectiveness, safety, limitations and issues still to be addressed with RDN.

Schmieder, R., Redon, J., Grassi, G., Kjeldsen, S., Mancia, G., Narkiewicz, K., et al. (2012). ESH position paper: renal denervation - an interventional therapy of resistant hypertension. JOURNAL OF HYPERTENSION, 30(5), 837-841 [10.1097/HJH.0b013e328352ce78].

ESH position paper: renal denervation - an interventional therapy of resistant hypertension

GRASSI, GUIDO;MANCIA, GIUSEPPE;PARATI, GIANFRANCO;
2012

Abstract

Experts from the European Society of Hypertension prepared this position paper in order to summarize current evidence, unmet needs and practical recommendations on the application of percutaneous transluminal ablation of renal nerves [renal denervation (RDN)] as a novel therapeutic strategy for the treatment of resistant hypertension. The sympathetic nervous activation to the kidney and the sensory afferent signals to the central nervous system represent the targets of RND. Clinical studies have documented that catheter-based RDN decreases both efferent sympathetic and afferent sensory nerve traffic leading to clinically meaningful systolic and diastolic blood pressure (BP) reductions in patients with resistant hypertension. This position statement intends to facilitate a better understanding of the effectiveness, safety, limitations and issues still to be addressed with RDN.
Articolo in rivista - Articolo scientifico
Renal denervation; resistant hypertension
English
2012
30
5
837
841
none
Schmieder, R., Redon, J., Grassi, G., Kjeldsen, S., Mancia, G., Narkiewicz, K., et al. (2012). ESH position paper: renal denervation - an interventional therapy of resistant hypertension. JOURNAL OF HYPERTENSION, 30(5), 837-841 [10.1097/HJH.0b013e328352ce78].
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/32048
Citazioni
  • Scopus 224
  • ???jsp.display-item.citation.isi??? 191
Social impact